The company itself is the constraint: demand outrunning its own ability to take it on, and management is spending to rai
The model's full reasoning — Q3 2018 call → NOWe need to determine if management conveys that the company's own capability is the binding limit on growth, and that they are actively spending/building/hiring NOW to raise that limit, treating it as central. Let's scan the transcript for relevant statements. Key points: - Jim Robinson on ARISTADA: "We will continue to make additional investments in ARISTADA to match the opportunity ahead. During the fourth quarter, we will further expand our field and hospital-based sales force by approximately 50 sales representatives based on the opportunities we are identifying and the encouraging trends that we are seeing." This suggests they are expanding sales force to match opportunity, implying demand is there and they are building capability. But is this the central task? They mention it as part of ongoing investments. - Richard Pops on pipeline: "we continue to invest in our internal research and discovery efforts and expanding our capabilities in biologics." That's more R&D. - On 5461: "we've done enormous amount of preparation for launch of 5461, but we won't pull the trigger on hiring the next level of sales force expansion until such time as we really have a sense that the drug is going to be approved." So they are not hiring yet for 5461; it's contingent. - On 3831: not much about capacity. - On VIVITROL: they talk about expanding capabilities: "We are expanding our capabilities to respond to the evolving market dynamics, including through the addition of key account managers and field-based reimbursement managers." That is hiring to expand capability. But is it described as the binding limit? They say "to respond to the evolving market dynamics" - not necessarily that demand is pressing against capacity. - On ARISTADA: they are adding 50 sales reps. They say "based on the opportunities we are identifying and the encouraging trends that we are seeing." That suggests they see demand and are expanding to capture it. But is it the central task? They also talk about other things. - The overall tone: They are investing in commercial organization, R&D, etc. But is there a statement that the company's own capability is the ceiling? For example, "we could do more business than we can handle" or "demand is running ahead of our ability to serve." I don't see that explicit.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| BRBR | BellRing Brands, Inc. | Q4 2023 | 2023-11-21 | B+ |
| PRPH | ProPhase Labs, Inc. | Q1 2023 | 2023-05-11 | F |
| TSSI | TSS, Inc. | Q4 2022 | 2023-04-03 | D |
| TACT | TransAct Technologies Incorporated | Q4 2022 | 2023-03-08 | A |
| CHE | Chemed Corporation | Q3 2022 | 2022-11-01 | B+ |
| CRL | Charles River Laboratories International | Q2 2022 | 2022-08-03 | C |
| SYM | Symbotic Inc. | Q3 2022 | 2022-08-01 | B+ |
| JBHT | J.B. Hunt Transport Services, Inc. | Q2 2022 | 2022-07-19 | C+ |
| OGI | OrganiGram Holdings Inc. | Q3 2022 | 2022-07-14 | B+ |
| FLUX | Flux Power Holdings, Inc. | Q2 2022 | 2022-02-10 | D |
| GTES | Gates Industrial Corporation plc | Q4 2021 | 2022-02-07 | C+ |
| FORM | FormFactor, Inc. | Q4 2021 | 2022-02-02 | B |
| GFS | GLOBALFOUNDRIES Inc. | Q3 2021 | 2021-11-30 | A |
| HNRG | Hallador Energy Company | Q3 2021 | 2021-11-09 | C+ |
| FSS | Federal Signal Corporation | Q1 2018 | 2018-05-12 | A |
| AOSL | Alpha and Omega Semiconductor Limited | Q2 2018 | 2018-02-07 | B |
| LIND | Lindblad Expeditions Holdings, Inc. | Q2 2017 | 2017-08-06 | C |
| ZBH | Zimmer Biomet Holdings, Inc. | Q2 2017 | 2017-07-30 | F |
| GOGO | Gogo Inc. | Q1 2016 | 2016-05-06 | C+ |
ZBH · Q2 2017 → YESThe question is whether management conveys that the company's own ability to serve, supply, or take on business is the binding limit, and they're actively spending/building/hiring now to raise that li...YES The transcript shows management framing the Warsaw North Campus production delays and resulting back orders as the direct constraint on meeting existing customer demand and recapturing lost business, with steady market demand present but supply gating growth. They describe actively investing now in manufacturing remediation, quality enhancements, safety stock building, and sales force incentives and hires to restore full supply and return to offense, treating these as the central priority to expand capability and capture opportunities. This matches the criteria of internal capability as the binding limit and immediate action to raise it. The remediation is presented as urgent and ongoing rather than routine catch-up. The answer is YES.
FORM · Q4 2021 → YESThe question is whether management conveys that their own ability to serve/supply is the binding limit, and they're actively expanding now. YES The transcript shows management explicitly framing the company's internal limits—labor shortages in U.S. factories and extended lead times from sub-component delays—as the immediate ceiling on revenue growth, while simultaneously describing active, ongoing capital investments, facility expansions (Livermore), tool and labor additions, and supplier qualification efforts as the central priority to raise that ceiling and meet surging customer demand. This dual situation is presented as a present-tense reality driving the $850 million target path. The supply-chain component is acknowledged but subordinated to the claim that demand is outrunning current capability, and the build-out is treated as the key task ahead rather than routine maintenance.
FLUX · Q2 2022 → YESThe question is: Does management convey that the company's own ability to serve, supply, or take on business has become the binding limit on how big it can be right now — that real demand is pressing ...YES The transcript shows management explicitly framing the company's production capacity as the current binding limit: "We can’t build packs fast enough to keep up with the demand" and noting that supply-chain constraints (especially electronic components) are preventing them from serving the robust order flow and record backlog.